Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Director Sells $97,282.60 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Elizabeth Kwo sold 4,010 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $24.26, for a total transaction of $97,282.60. Following the sale, the director owned 14,116 shares of the company’s stock, valued at $342,454.16. The trade was a 22.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

NASDAQ KMTS opened at $27.14 on Friday. The stock has a market capitalization of $1.62 billion, a P/E ratio of -10.16 and a beta of 0.62. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $30.00. The business’s fifty day moving average is $25.22 and its two-hundred day moving average is $22.79. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The company had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. On average, research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KMTS shares. BTIG Research restated a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Royal Bank Of Canada set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies presently has an average rating of “Hold” and an average price target of $28.38.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Brown Advisory Inc. lifted its holdings in shares of Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after buying an additional 428,996 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in Kestra Medical Technologies during the fourth quarter valued at approximately $9,282,000. Next Century Growth Investors LLC raised its position in Kestra Medical Technologies by 154.5% during the fourth quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company’s stock valued at $12,354,000 after acquiring an additional 282,832 shares in the last quarter. Seven Grand Managers LLC acquired a new stake in Kestra Medical Technologies in the fourth quarter valued at approximately $2,652,000. Finally, Eventide Asset Management LLC grew its position in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares in the last quarter.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.